> Dendreon ($DNDN) has appointed retired biotech exec W. Thomas Amick as its new CEO. Story
> New Mexico-based Agilvax has scored $2 million in Series A funding to develop its virus-like particle technology. Report
> Merck's ($MRK) shingles vaccine Zostavax remains effective after chemotherapy, a study found. Release
> PaxVax has named Jonathan Klock as its North American sales and marketing VP and Jeremy Gowler as its VP of global marketing. Release
> GeoVax has entered a clinical development license agreement with Valneva for its HIV/AIDS vaccines. Release
> The NIH has awarded $3.5 million in grants to Profectus BioSciences for HIV-related vaccine development. More